pharma · Primary Mitochondrial Myopathy · Advanced Solid Tumors, Advanced Breast Cancer · OKUR
OnKure Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
OnKure Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
Development asset linked to OnKure Therapeutics in public FDA and regional records.
Development asset linked to OnKure Therapeutics in public FDA and regional records.